Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05745961
Status:
RECRUITING
Last Update Posted:
2023-09-28
First Post:
2023-02-16
Brief Title:
Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension PAH
Sponsor:
Imperial College London
Organization:
Imperial College London
Study Overview
Official Title:
Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension PAH
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to determine whether there is an increase in the TSPO PET signal measured with the radioligand 11CPBR28 in the lungs of patients living with PAH relative to age matched controls If so TSPO PET may be a useful technique to non-invasively monitor response to therapy To do this we will perform 2 11CPBR28 PET scans The first will quantify the total 11CPBR28 PET signal This signal is a combination of the specific signal VS and the nonspecific signal VND The second scan will be performed following dosing with an unlabelled TSPO ligand By directly measuring the total 11CPBR28 signal scan 1 and the nonspecific 11CPBR28 signal scan 2 we can therefore calculate the specific 11CPBR28 signal and hence the amount of TSPO in the lung
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None